Journal
VACCINE
Volume 29, Issue 42, Pages 7251-7260Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.07.020
Keywords
Dengue fever; Vaccine development; Dengue virus; DEN-2 PDK-53 virus; Recombinant viral vaccine
Categories
Funding
- Intramural CDC HHS [CC999999] Funding Source: Medline
Ask authors/readers for more resources
Dengue. virus infection is the leading arboviral cause of disease worldwide. A vaccine is being developed based on the attenuated DEN-2 virus, DEN-2 PDK-53. In this review, we summarize the characteristics of the parent DEN-2 PDK-53 strain as well as the chimeric viruses containing the prM and E genes of DEN-1, DEN-3 or DEN-4 virus in the genetic backbone of the DEN-2 PDK-53 virus (termed DENVax). Tetravalent DENVax formulations containing cloned. fully sequenced isolates of the DEN-2 PDK-53 virus and the three chimeras have been evaluated for safety and efficacy in preclinical animal models. Based on the safety, immunogenicity and efficacy in preclinical studies, Phase 1 clinical testing of DENVax has been initiated. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available